Scientific Symposium Oral Presentations
October 2003, Houston, Texas
Session I: Overview, New FA Genes and Molecular Diagnosis
Session II: Protein Function: DNA Damage and Repair
Session III: Protein Function: Signal Transduction
Session IV: Bone Marrow Transplantation
Session V: Gene Therapy, Aplastic Anemia and Miscellaneous
Session VI: Carcinogenesis
Session VII: Leukemogenesis
Ruhikant Meetei, PhD presenting his research.

Session I: Overview, New FA Genes and Molecular Diagnosis

Ruhikant Meetei, PhD National Institute on Aging, National Institutes of Health, Baltimore, Maryland A Novel Ubiquitin Ligase is Deficient in Fanconi Anemia.
Annette Medhurst, PhD Vrije Universiteit Medical Center, Amsterdam, The Netherlands FANCL is an Intrinsic Part of the FA Core Complex.
Marieke Levitus, MSc Vrije Universiteit Medical Center, Amsterdam, The Netherlands Characteristics of the New FA Complementation Groups I and J.
Gerard Pals, PhD Vrije Universiteit Medical Center, Amsterdam, The Netherlands Clinical Molecular Diagnosis for All Known Fanconi Anemia Genes.

Session II: Protein Function: DNA Damage and Repair

Kevin Hiom, PhD MRC Laboratory of Molecular Biology, Cambridge, UK BRCA1-Independent Ubiquitination of FANCD2.
Jordi Surrallés, PhD Universitat Autónoma de Barcelona, Barcelona, Spain A Recombination Independent Role for the Fanconi Anemia/BRCA Pathway.
Andreas Rothfuss, PhD Oregon Health and Science University, Portland, Oregon Evidence for a DNA Double-Strand Break-Dependent Activation of the Fanconi Anemia/BRCA2 Pathway During the Repair of DNA-Interstrand Crosslinks.
K. J. Patel, PhD, MRCP MRC Laboratory of Molecular Biology, U. of Cambridge, UK Genetic Interactions Between the Fanconi Anaemia Pathway, Recombination and End Joining Repair in DT40 Cells.
Robb Moses, MD Oregon Health and Science University, Portland, Oregon Epistasis Analysis of BRCA1 and BRCA2 in the Fanconi Anemia Pathway Using siRNA.
Toshiyasu Taniguchi, MD, PhD Dana-Farber Cancer Institute, Boston, Massachusetts MDC1, 53BP, BRCA1 and BARD1 are Required for the Efficient IR-Inducible Assembly of FANCD2 Foci.
Stephen Meyn, MD, PhD, FRCP(C) Hospital for Sick Children, Toronto, Ontario, Canada Nuclear Dynamics of FANCD2, FANCA, BLM and ATM Following DNA Damage.
Barbara Godthelp, PhD Leiden University Medical Center, Leiden, The Netherlands DNA Damage-Induced Rad51 Foci Make an Important Difference.
Sarah L. Donohue, PhD University of Minnesota Medical School, Minneapolis, Minnesota Hypersensitivity of Fanconi Anemia Fibroblasts to Diepoxybutane Results from Rad51 Overexpression.
Alexandra Sobeck, PhD Oregon Health and Science University, Portland, Oregon Xenopus FANCD2 Binds to Chromatin in a Replication and DNA Damage-Dependent Manner.
Gary Kupfer, MD University of Virginia, Charlottesville, Virginia FA Core Complex Forms Nuclear Foci During S Phase.

Session III: Protein Function: Signal Transduction

Marieke von Lindern, PhD Institute of Hematology, Erasmus MC, Rotterdam, The Netherlands Erythropoietin-Induced Signal Transduction is Impaired in Mice Lacking FancA or FancG Protein.
Isabelle Brodeur, PhD Hôpital St-Francois d'Assise, Québec City, Québec, Canada IL-6 Signaling Pathway in Fanconi Anemia Group C Model.
Laura Haneline, MD Cancer Research Institute, Indiana University School of Medicine, Indianapolis, Indiana Oxidant Induced Apoptosis in Fancc-/- Cells is Dependent on a Redox-Sensitive Pathway.
Xiaxin Li, PhD, MD Cancer Research Institute, Indiana University School of Medicine, Indianapolis, Indiana Interferon-Gamma (IFN-gamma) Non-Myeloablative Conditioning Reduces Stem Cell Repopulating Ability and Enhances Engraftment in Fanconi Anemia Type C FancC-/- Mice.
Filippo Rosselli, PhD Institut Gustave Roussy, Villejuif, France The FANC/NBS1 and CHK1 Pathways Equally Contribute to the Cross-Links-Induced S-Phase Checkpoint Activation Downstream ATR.
Giovanni Pagano, Sc.D Italian National Cancer Institute, Center for Pediatric Oncology Research, Mercogliano, Italy Multiple Evidence for an In Vivo Prooxidant State in Fanconi Anemia Patients.

Session IV: Bone Marrow Transplantation

John Wagner, MD Pediatric Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota Uniform Engraftment and Survival after Fludarabine-Based Regimen without Radiation in Fanconi Anemia Patients Undergoing Genotypically Identical Donor Hematopoietic Cell Transplantation.
Margaret MacMillan, MD Pediatric Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota High Probability of Survival in Standard Risk Patients with Fanconi Anemia after Alternate Donor Hematopoietic Cell Transplantation (HCT).
Ricardo Pasquini, MD, PhD Hospital de Clinicas, Federal University of Parana, Curitiba, Brazil Bone Marrow Transplantation (BMT) for Fanconi Anemia Decreasing the Cyclophosphamide Dose without Irradiation.
Eliane Gluckman, MD Bone Marrow Transplantation, Hôpital Saint-Louis, Paris, France Results of Unrelated Cord Blood Transplant in FA: A Eurocord Registry Study.
Farid Boulad, MD Memorial Sloan-Kettering Cancer Center, New York City, New York Fludarabine (Flu) Based Cytoreductive Regiment and T-cell Depleted Grafts From Unrelated or Mismatched Related Donors.
Ingrid Kuehnle, MD Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas CD45 and CD52 Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation for Patients with Fanconi Anemia Who Lack HLA Matched Sibling Donors.
Wolfram Ebell, MD Charité, Medical Faculty of the Humboldt University of Berlin, Germany Current Results, Pharmacokinetic and Chimerism Analyses in FA Patients Receiving Unrelated Transplants According to the GEFA Protocol.

Session V: Gene Therapy, Aplastic Anemia and Miscellaneous

Uma Lakshmipathy, PhD Stem Cell Institute, University of Minnesota, Minneapolis, Minnesota Gene Correction by Homologous Recombination in Multipotent Adult Progenitor Cells: Frequency of Gene Targeting in FANCC-/- Cells.
Frank Kruyt, PhD Vrije Universiteit Medical Center, Amsterdam, The Netherlands The FA Pathway as a Potential Target for Cancer Gene Therapy Sensitizing Tumor Cells for Cisplatin using an Adenoviral Vector Overexpressing Dominant Negative FANCA.
Jasmine Wong, MSc Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada Reproductive and Hematopoietic Defects in a Fanconi Anemia Group A Mouse Model.
Blanche Alter, MD, MPH Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland Individualized Risk of Adverse Events in Fanconi's Anemia.
Philippe Guardiola, MD Fred Hutchinson Cancer Research Center, Seattle, Washington Use of Gene Expression Profiling to Detect Transcriptional Differences Between FANCA, FANCC, and FANCG Deficient Primary Fibroblasts: A Powerful Tool to Analyze Biological Processes Dysregulated in Fanconi Anemia and to Predict Complementation Group.
Grover Bagby, Jr., MD Oregon Cancer Institute, Portland, Oregon An Interim Analysis of Microarray Data from the Fanconi Anemia Transcriptome Consortium.
Susan Rose, MD Cincinnati Children's Medical Center, Cincinnati, Ohio Endocrine Effects of Fanconi Anemia.

Session VI: Carcinogenesis

Arleen Auerbach, PhD The Rockefeller University, New York City, New York IFAR 2003: Unique Phenotype Associated with Biallelic BRCA2 Mutations Includes High Risk of Brain Tumors, Wilms Tumors and Early Onset Acute Leukemia.
Scott Houghtaling, Graduate Student Oregon Health and Science University, Portland, Oregon Heterozygosity for p53 (Trp53-/+) Accelerates the Tumor Phenotype of Fanconi Anemia Complementation Group D2 (Fancd2) Knockout Mice.
David Kutler, MD Memorial Sloan-Kettering Cancer Center, New York City, New York Chromosomal Aberrations in Fanconi Anemia-associated Squamous Cell Carcinomas Differ From Sporadic Squamous Cell Carcinomas from the General Population.
Ruud Brakenhoff, PhD Vrije Universiteit Medical Center, Amsterdam, The Netherlands Genetic Characterization of Head and Neck Squamous Cancer Cell Lines of FA Patients.
Michiel van der Heijden, MD Johns Hopkins University, Baltimore, Maryland Fanconi Anemia Gene Defects in Pancreatic Cancer.
Larry Thompson, PhD Lawrence Livermore National Laboratory, Livermore, California FancG Knockout CHO Cells have an Increased Rate of Gene Amplification, Which May Result from Increased Production of Double-Strand Breaks During DNA Replication.

Session VII: Leukemogenesis

Betsy Hirsch, PhD University of Minnesota Medical School, Minneapolis, Minnesota Recurring Clonal Chromosomal Abnormalities in Fanconi Anemia: Characterization and Association with Bone Marrow Pathology.
Heidemarie Neitzel, PhD Institute of Human Genetics, Charité, Humboldt University, Berlin, Germany Chromosomal Aberrations in Bone Marrow of FA Patients: Clonal Evolution, Time Course of Clonal Outgrowth, and Correlation with the Clinical Course.
Holger Tönnies, PhD Institute of Human Genetics, Charité, Humboldt University, Berlin, Germany Establishment of a FA-Specific Interphase FISH-assay for the Sensitive Detection of MDS- and AML-associated Chromosomal Imbalances on Uncultivated Peripheral Blood Cells.
Brian Freie, PhD Indiana University School of Medicine, Indianapolis, Indiana Fanconi Anemia Type C and p53 Cooperate in Apoptosis and Tumorigenesis.
Qishen Pang, PhD Oregon Health and Science University, OHSU Cancer Institute, Portland, Oregon Modeling Clonal Adaptation in FA: Nucleophosmin Inhibits the Eukaryotic Initiation Factor 2 Kinase PKR and Induces Myeloid Differentiation Arrest in Mutant FA-C Cells.
Fanconi Anemia Research Fund, Inc. Fanconi Anemia Research Fund, Inc.